| Not Yet Recruiting | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Red NCT07429487 | Centre Antoine Lacassagne | N/A |
| Not Yet Recruiting | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma NCT07529808 | BigHat Biosciences, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer NCT07464756 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma NCT07059611 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Not Yet Recruiting | A Multicentre Prospective Cohort Study of The Gastric Precancerous Epithelial Pathway Using High-Definition En NCT07486518 | Asian Institute of Gastroenterology, India | — |
| Not Yet Recruiting | A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer NCT07507526 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Magnetic Sentinel Lymph Node Mapping in Gastric Cancer NCT05038098 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413 | IDEAYA Biosciences | Phase 1 |
| Recruiting | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642 | Avacta Life Sciences Ltd | Phase 1 |
| Recruiting | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients W NCT07282912 | Yale University | Phase 2 |
| Not Yet Recruiting | An Observational Study on Gastric Cancer in High-risk Individuals NCT07438418 | Fudan University | — |
| Not Yet Recruiting | Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Inst NCT07266025 | Shanghai Zhongshan Hospital | Phase 2 |
| Active Not Recruiting | Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management NCT07522320 | Unidade Local De Saúde Do Norte Alentejano | — |
| Not Yet Recruiting | Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal o NCT07000253 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 / Phase 3 |
| Not Yet Recruiting | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors NCT07252661 | AccSalus Biosciences, Inc. | Phase 1 |
| Withdrawn | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers NCT05296005 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for R NCT07059299 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 1 |
| Enrolling By Invitation | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gas NCT07139951 | Mayo Clinic | Phase 2 |
| Recruiting | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186 | Plexium, Inc. | Phase 1 |
| Recruiting | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149 | Normunity AccelCo, Inc. | Phase 1 |
| Recruiting | A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab NCT07263386 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Not Yet Recruiting | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer NCT07007182 | Jinbo Yue | Phase 2 |
| Recruiting | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanc NCT07152405 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patie NCT07001748 | ECOG-ACRIN Cancer Research Group | Phase 2 / Phase 3 |
| Recruiting | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients NCT07103668 | Suzhou Immunofoco Biotechnology Co., Ltd | Phase 3 |
| Active Not Recruiting | Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany NCT06902337 | Medizinische Hochschule Brandenburg Theodor Fontane | — |
| Recruiting | Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors NCT07021066 | SystImmune Inc. | Phase 1 |
| Recruiting | Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detect NCT06943781 | Fudan University | — |
| Recruiting | Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma NCT07427992 | European Institute of Oncology | — |
| Recruiting | Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopi NCT07029269 | Zuoyi Jiao | Phase 3 |
| Recruiting | Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric NCT07034742 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | EARLY_Phase 1 |
| Not Yet Recruiting | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Local NCT06942767 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ NCT06985602 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors NCT07001592 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 1 |
| Not Yet Recruiting | Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer NCT06888037 | Ruijin Hospital | Phase 2 |
| Not Yet Recruiting | Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic G NCT06914687 | Fudan University | Phase 2 |
| Recruiting | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer NCT06028737 | Ukrainian Society of Clinical Oncology | Phase 2 / Phase 3 |
| Not Yet Recruiting | Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients NCT06857786 | Peking University | Phase 1 |
| Active Not Recruiting | Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy NCT06938139 | Fujian Medical University | — |
| Not Yet Recruiting | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer NCT06871527 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally NCT06808971 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Enrolling By Invitation | Laparoscopic Staging for Stage III Gastric Cancer NCT07533825 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Recruiting | Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery NCT06289374 | Imperial College London | — |
| Recruiting | Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ NCT06761846 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer NCT06798376 | Chinese PLA General Hospital | — |
| Enrolling By Invitation | Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences( NCT06862479 | Unidade Local de Saúde Santa Maria | — |
| Active Not Recruiting | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, NCT06504615 | Bristol-Myers Squibb | — |
| Recruiting | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers NCT06422403 | National University Hospital, Singapore | Phase 2 |
| Recruiting | The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Can NCT06881043 | The First Hospital of Jilin University | — |
| Terminated | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMAR NCT06560645 | Prelude Therapeutics | Phase 1 |
| Active Not Recruiting | CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastri NCT06667050 | West China Hospital | Phase 2 |
| Not Yet Recruiting | A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilim NCT06586294 | Akeso | Phase 1 / Phase 2 |
| Completed | PG Versus TG for Advanced PGC NCT06614439 | National Taiwan University Hospital | N/A |
| Completed | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors NCT06549816 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI NCT06333314 | UNICANCER | Phase 2 |
| Recruiting | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors NCT06399757 | Apollo Therapeutics Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemo NCT06454435 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma NCT06340711 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | A Study Collecting Health Information to Understand and Prevent Gastric Cancer NCT06370143 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer NCT06196697 | Harbin Medical University | Phase 2 |
| Terminated | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or NCT05567835 | Baylor College of Medicine | Phase 2 |
| Recruiting | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanc NCT07334431 | Henan Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer NCT06123338 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarci NCT06206733 | AskGene Pharma, Inc. | Phase 3 |
| Recruiting | A Study of KK2269 in Adult Participants With Solid Tumors NCT06266299 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Completed | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesopha NCT07529613 | National Cancer Center Hospital East | Phase 1 / Phase 2 |
| Recruiting | Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study NCT06059495 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Active Not Recruiting | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastr NCT05836584 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasi NCT05802056 | Mayo Clinic | Phase 1 |
| Recruiting | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma NCT06353152 | Peking University | Phase 1 |
| Not Yet Recruiting | Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistan NCT06118645 | China Medical University, China | Phase 2 |
| Recruiting | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer NCT06038578 | Toray Industries, Inc | Phase 2 |
| Recruiting | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Pos NCT05977998 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With A NCT05476796 | UNICANCER | Phase 2 |
| Completed | Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastr NCT04535414 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Recruiting | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junc NCT06496789 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Unknown | Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine NCT05800236 | University Hospital, Bordeaux | N/A |
| Recruiting | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limit NCT05753306 | Mayo Clinic | Phase 2 |
| Recruiting | Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer NCT05709574 | University of Arizona | Phase 2 |
| Unknown | Klotho _ LRP-6 _ Gastric Adenocarcinoma NCT05293535 | Assiut University | — |
| Recruiting | Evaluating Novel Therapies in ctDNA Positive GI Cancers NCT05482516 | Georgetown University | Phase 3 |
| Completed | Stomach Cancer Exosome-based Detection NCT06342427 | City of Hope Medical Center | — |
| Recruiting | The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study NCT05804331 | Western Sydney Local Health District | — |
| Unknown | Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastri NCT05816863 | Peking University Cancer Hospital & Institute | — |
| Unknown | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer NCT05705635 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Recruiting | Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive NCT06466902 | Azienda Ospedaliero-Universitaria di Parma | — |
| Recruiting | MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal NCT05723718 | Medical University of Lublin | — |
| Terminated | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma NCT05687617 | Laval University | Phase 2 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Terminated | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HE NCT05311176 | Imugene Limited | Phase 2 |
| Unknown | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer NCT05235906 | Sun Yat-sen University | Phase 2 |
| Unknown | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors NCT05393986 | Peking University | Phase 1 |
| Recruiting | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastro NCT05365581 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy NCT05394740 | National Cancer Center Hospital East | Phase 1 / Phase 2 |
| Withdrawn | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With NCT04931420 | University of Chicago | Phase 2 |
| Suspended | Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma NCT05135845 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Active Not Recruiting | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitab NCT05034887 | National Cancer Center Hospital East | Phase 2 |
| Active Not Recruiting | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) NCT05002127 | ALX Oncology Inc. | Phase 2 / Phase 3 |
| Completed | Multimodal Model Predicts Recurrence NCT06690268 | Qun Zhao | — |
| Unknown | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophage NCT04999332 | National Cheng-Kung University Hospital | Phase 2 |
| Active Not Recruiting | Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01) NCT05076279 | Seoul National University Bundang Hospital | N/A |
| Recruiting | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) NCT05177133 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Unknown | Gastrectomy Outcomes in Elderly Patients NCT05071755 | Marmara University | — |
| Withdrawn | Study of FMT Combined With Nivolumab in Gastric Cancer NCT05001360 | Fujian Cancer Hospital | N/A |
| Completed | A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcino NCT05008783 | Akeso | Phase 3 |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Terminated | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer NCT03042169 | University Hospital, Lille | Phase 3 |
| Unknown | Transcriptomic Signatures in Gastric Adenocarcinoma NCT05319392 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | — |
| Unknown | A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu NCT05249244 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | — |
| Recruiting | Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Rese NCT04850729 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GAST NCT07178808 | Banner Health | Phase 2 |
| Terminated | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab NCT04779151 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Unknown | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors NCT04764084 | Peking University Cancer Hospital & Institute | Phase 1 |
| Unknown | Outcome of Radiation Therapy in Operated Gastric Cancer NCT04810663 | Assiut University | — |
| Completed | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HE NCT04499924 | Seagen Inc. | Phase 2 / Phase 3 |
| Unknown | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) NCT04739202 | Hospices Civils de Lyon | Phase 2 |
| Terminated | A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) NCT04675983 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Withdrawn | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pa NCT05056805 | M.D. Anderson Cancer Center | N/A |
| Completed | Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnose NCT03986502 | Fred Hutchinson Cancer Center | N/A |
| Completed | Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer NCT06250075 | Universidade Federal do Amazonas | N/A |
| Terminated | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors NCT04682431 | Ikena Oncology | Phase 1 |
| Active Not Recruiting | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma NCT04111172 | Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection NCT04581473 | CARsgen Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophagea NCT04517747 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | N/A |
| Terminated | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma NCT04604132 | Basilea Pharmaceutica | Phase 1 / Phase 2 |
| Active Not Recruiting | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER NCT04430738 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies NCT04114136 | Dan Zandberg | Phase 2 |
| Active Not Recruiting | Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma NCT04523818 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophag NCT04503967 | Shanghai Zhongshan Hospital | Phase 2 |
| Terminated | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal NCT04363801 | Leap Therapeutics, Inc. | Phase 2 |
| Recruiting | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and G NCT04150640 | University of Wisconsin, Madison | Phase 2 |
| Completed | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study NCT04065139 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Assessment of What Patients and Healthcare Providers Value NCT04483349 | M.D. Anderson Cancer Center | — |
| Completed | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With NCT04034251 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer NCT04943406 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Completed | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid NCT04344795 | Tempest Therapeutics | Phase 1 |
| Withdrawn | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma NCT03739801 | University of Southern California | Phase 1 / Phase 2 |
| Completed | Adjuvant PIPAC in Gastric Cancer Patients NCT04047004 | Michael Bau Mortensen | Phase 1 |
| Active Not Recruiting | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (K NCT04152499 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Terminated | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer NCT04162665 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma NCT04164979 | University of California, Irvine | Phase 2 |
| Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) NCT04290806 | iOMEDICO AG | — |
| Unknown | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer NCT04121039 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Rando NCT04190745 | Zhejiang Cancer Hospital | Phase 2 |
| Completed | A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastr NCT04161781 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | A Study of LY3435151 in Participants With Solid Tumors NCT04099277 | Eli Lilly and Company | Phase 1 |
| Terminated | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma NCT04089904 | University of Chicago | Phase 2 |
| Terminated | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors NCT04032704 | Seagen Inc. | Phase 2 |
| Recruiting | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma NCT04047953 | Peking University Cancer Hospital & Institute | N/A |
| Completed | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma NCT04074343 | University of California, Irvine | Phase 1 |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Unknown | This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort NCT03780608 | Samsung Medical Center | Phase 2 |
| Active Not Recruiting | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatme NCT03959293 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Completed | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma NCT03802591 | CStone Pharmaceuticals | Phase 3 |
| Completed | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas NCT03894618 | Shattuck Labs, Inc. | Phase 1 |
| Unknown | Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma NCT03973008 | Zhejiang Cancer Hospital | Phase 3 |
| Unknown | Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study NCT04194463 | Newcastle-upon-Tyne Hospitals NHS Trust | N/A |
| Unknown | Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma NCT03788174 | Fujian Cancer Hospital | Phase 2 |
| Terminated | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Canc NCT03809624 | Inhibrx Biosciences, Inc | Phase 1 |
| Completed | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas NCT03783936 | Ashwin Somasundaram | Phase 2 |
| Completed | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-l NCT03852251 | Akeso | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With C NCT03735290 | Mendus | Phase 1 |
| Active Not Recruiting | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer NCT03776487 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Ade NCT03686488 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Unknown | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic an NCT04773769 | Auxilio Mutuo Cancer Center | N/A |
| Unknown | Study of the Combination of Apatinib and POF NCT03707639 | Fujian Cancer Hospital | Phase 2 |
| Active Not Recruiting | Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric C NCT03997162 | City of Hope Medical Center | — |
| Unknown | Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma NCT03631615 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma. NCT03691454 | Peking University | Phase 2 / Phase 3 |
| Unknown | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neo NCT03468244 | Changhai Hospital | N/A |
| Completed | OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma NCT03429816 | University Hospital Heidelberg | N/A |
| Unknown | mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) NCT03288350 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 |
| Recruiting | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or NCT03161522 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | TAS102 in Combination With NAL-IRI in Advanced GI Cancers NCT03368963 | Emory University | Phase 1 / Phase 2 |
| Completed | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies NCT03365791 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Phase I Study of the Combination of Apatinib and POF NCT03244774 | Fujian Cancer Hospital | Phase 1 |
| Completed | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers NCT03195699 | Tvardi Therapeutics, Incorporated | Phase 1 |
| Completed | Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcino NCT03141034 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Eps NCT03257163 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction o NCT03196232 | George Albert Fisher | Phase 2 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers NCT03122548 | Aduro Biotech, Inc. | Phase 2 |
| Unknown | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer NCT03399071 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Unknown | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors NCT03507998 | Curegenix Inc. | Phase 1 |
| Completed | Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology NCT03092518 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Par NCT03042611 | Elevar Therapeutics | Phase 3 |
| Completed | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal NCT02898077 | Eli Lilly and Company | Phase 3 |
| Terminated | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors NCT02952989 | Seagen Inc. | Phase 1 |
| Completed | Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers NCT03246516 | University Hospital, Lille | N/A |
| Completed | Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma NCT03814759 | Yonsei University | Phase 2 |
| Unknown | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC NCT02915432 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gas NCT02830594 | City of Hope Medical Center | Phase 2 |
| Terminated | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Can NCT02862535 | Gilead Sciences | Phase 1 |
| Completed | Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer NCT02891447 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in A NCT02864381 | Gilead Sciences | Phase 2 |
| Completed | Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcin NCT02628951 | Samsung Medical Center | Phase 2 |
| Completed | Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progr NCT02589496 | Samsung Medical Center | Phase 2 |
| Completed | Resilience and Exercise in Advanced Cancer Treatment NCT02680990 | Milton S. Hershey Medical Center | N/A |
| Terminated | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies NCT02638909 | Criterium, Inc. | Phase 2 |
| Terminated | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal NCT02485834 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocar NCT02545504 | Gilead Sciences | Phase 3 |
| Completed | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer NCT02514551 | Eli Lilly and Company | Phase 2 |
| Completed | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced G NCT02494583 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitio NCT02443324 | Eli Lilly and Company | Phase 1 |
| Completed | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Can NCT02443883 | Eli Lilly and Company | Phase 2 |
| Unknown | Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EG NCT02512380 | Chinese Academy of Medical Sciences | Phase 3 |
| Completed | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal J NCT02370498 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma NCT02801955 | Bezmialem Vakif University | — |
| Completed | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Ju NCT02335411 | Merck Sharp & Dohme LLC | Phase 2 |
| Suspended | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advan NCT02366819 | University of Chicago | Phase 4 |
| Completed | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer NCT02333188 | University of Chicago | Phase 1 |
| Unknown | Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Sco NCT02781285 | Shanghai University of Traditional Chinese Medicine | — |
| Completed | Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients Wit NCT02448290 | Samsung Medical Center | Phase 2 |
| Completed | Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients NCT02287168 | Bezmialem Vakif University | EARLY_Phase 1 |
| Completed | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer NCT02128243 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab NCT02013154 | Leap Therapeutics, Inc. | Phase 1 |
| Completed | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer NCT02082210 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Unknown | A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer NCT02144727 | National Cancer Center, Korea | Phase 3 |
| Unknown | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer NCT02007148 | International Group of Endovascular Oncology | Phase 2 |
| Completed | Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcin NCT01932580 | McGill University | Phase 2 |
| Unknown | Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma NCT01880632 | Shanghai Zhongshan Hospital | Phase 2 |
| Completed | S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma NCT02495493 | Yonsei University | Phase 2 |
| Active Not Recruiting | D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma NCT01882933 | Hospices Civils de Lyon | Phase 3 |
| Completed | Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients NCT01794026 | Bezmialem Vakif University | EARLY_Phase 1 |
| Completed | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer NCT01631552 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma NCT01757171 | Weill Medical College of Cornell University | Phase 2 |
| Unknown | Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer NCT01641783 | Yanqiao Zhang | Phase 2 |
| Completed | Carnoy's Solution Versus Formalin in Rectal and Gastric Cancer Specimens Following: a Randomized Trial NCT02629315 | Instituto do Cancer do Estado de São Paulo | N/A |
| Terminated | Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study NCT01558011 | National Health Research Institutes, Taiwan | Phase 2 |
| Completed | Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer NCT01567618 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Unknown | Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarci NCT01552980 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Unknown | SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer NCT01583361 | Lin Chen | Phase 3 |
| Completed | Trastuzumab Based Therapy in HER2 Positive AGC NCT03024450 | Shanghai Zhongshan Hospital | — |
| Completed | Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients NCT01336062 | Peking University | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced NCT01379807 | Grupo Gallego de Investigaciones Oncologicas | Phase 2 |
| Terminated | ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach) NCT01989858 | Mario Negri Institute for Pharmacological Research | Phase 3 |
| Completed | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gast NCT01178944 | Roswell Park Cancer Institute | Phase 2 |
| Completed | First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. NCT01129310 | AHS Cancer Control Alberta | Phase 2 |
| Unknown | Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer NCT01283217 | Yonsei University | Phase 3 |
| Unknown | Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma NCT00964080 | Mebiopharm Co., Ltd | Phase 1 / Phase 2 |
| Completed | NESC: Neoadjuvant Treatment of Gastric Adenocarcinoma NCT01565109 | Recherche clinique | Phase 2 |
| Terminated | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for S NCT00848783 | NYU Langone Health | Phase 2 |
| Terminated | Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adeno NCT00667420 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection NCT00464893 | Neovii Biotech | Phase 2 |
| Completed | Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer NCT00411151 | Johannes Gutenberg University Mainz | Phase 2 |
| Completed | Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma NCT00352833 | Neovii Biotech | Phase 2 |
| Terminated | Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma NCT00209079 | Emory University | Phase 2 |
| Completed | Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully R NCT00183911 | University of Southern California | Phase 2 |
| Completed | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer NCT00073502 | OSI Pharmaceuticals | Phase 2 |
| Completed | Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the St NCT00062374 | National Cancer Institute (NCI) | Phase 2 |
| No Longer Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors NCT04681248 | Leap Therapeutics, Inc. | — |